Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
Poster Session 89-F: Novel Antiretroviral Agents

September 27, 1999

This abstract reviews some early findings of a promising new drug of the NRTI class (the same class of drugs as AZT, d4T, and similar compounds). DAPD is active against both HIV-1 and the Hepatitis B virus. No major toxicities were seen in initial studies on mice, rats, or two species of monkey. When DAPD was tested against strains of HIV that are resistant to AZT, 3TC, or the non-nucleoside class (for instance, Sustiva and viramune), the drug continued to show good activity in suppressing HIV-1. This was also true for some viral strains with mutations that usually cause widespread resistance to NRTI's (i.e., the SS or SG insertion). This promising compound is in development by the Triangle Pharmaceutical Company, and human studies have begun in HIV-infected patients.
Abstract: DAPD: a Novel Nucleoside Inhibitor of HIV-1 Replication Is Active Against Drug-Resistant Isolates of HIV-1 from Patients Failing Standard Nucleoside Therapy (Paper 924)
Authored by: K. Borroto-Esoda, J. Mewshaw, et al.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement